{"success":true,"data":{"pressRelease":{"id":"18864","rtpr_id":"nGNEbQSGzm","ticker":"AIDR","exchange":"","all_tickers":["AIDR"],"title":"Rocket Doctor AI Reports Strong 2025 Results, Validating Physician-Led Model with Key U.S. Payer Contracts and AI Innovation","author":"Globe Newswire","published_at":"2026-05-04T12:00:00.433Z","article_body":"* Continued organic quarter over quarter revenue growth with growth of over\n30% from Q3 to Q4 2025 (from $529,123 in Q3 2025 to $697,340 for Q4 2025)\n \n*  Earnings per share for Q4, 2025: ($0.10) per share.\n\n\n*  Annual Revenues of $1.739 million in FY2025\n   *  Announced signed in-network contracts and credentialing with several\nmajor U.S. insurance companies. Extending Rocket Doctor’s U.S. total\nin-network reach to over 21 million members.\nVancouver, BC , May 04, 2026 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. (CSE:\nAIDR\n(https://www.globenewswire.com/Tracker?data=ZKL6DIwea7jTPl3bzR_Sti7kGX66ydkpvTo4ymZla64iTVmMTnprzDr0y9L7VcgF8h0WUivDJAJTBFnKow1xcOSZbRTwkpd2VrWmLlSnGek=),\nOTC: AIRDF\n(https://www.globenewswire.com/Tracker?data=LQ25uKv4ke4oRoh9LCOKYyC1oPFgnErd7MvwD0LFnkiO2HKqXDtFLwkTrLHAdM3JNLJmi5-9CYsOFZM7GdQ5v0yrvl952Z_C_RsqOTWCwuw=),\nFrankfurt: 939\n(https://www.globenewswire.com/Tracker?data=hmr8FtfLlvjfzMlHUbecVnjVRNXRqpUJv7dcOO8fngFWLGikIipzzvUfVtNpI80DVhZ-Akn8rq2JFIC8BAN7UXk7mOan_fOUkQNfmvJqd2ZoarsARyr14N7Z7Eesqvje))\n(“Rocket Doctor AI” or the “Company”), a physician-built, AI-powered\nhealthcare technology company focused on empowering doctors and expanding\naccess to high-quality care, is pleased to announce that it has filed its\naudited annual financial statements for the fiscal year and fourth quarter\nended December 31, 2025. The Company’s financial statements and\nManagement’s Discussion and Analysis (“MD&A”) are available under its\nprofile on SEDAR+ at www.sedarplus.ca.\n\nDr. Essam Hamza, CEO of Rocket Doctor AI Inc., commented: “2025 was a\nfoundational year for Rocket Doctor AI as we transitioned from proving our\nconcept to demonstrating the potential scalability of our physician-led model.\nFollowing the successful acquisition and integration of Rocket Doctor Inc.\nearlier this year, I am delighted with the significant progress the Company\nhas made. We have successfully shifted our focus toward operational\nexcellence, allowing us to support doctors in reducing administrative\nheadaches and overhead while expanding access to care for the populations that\nneed it most.”\n\nDr. Hamza continued: “The resilience of our marketplace is evidenced by our\n30% quarter-over-quarter organic growth from Q3 to Q4, led primarily by our\nestablished Canadian operations. This momentum is a direct result of our\ntechnological efficiencies and our recent strategic entry into the U.S. payer\nmarket. While U.S. operations represented less than 3% of our 2025 revenue,\nthe recent finalization of key payer agreements validates our infrastructure's\nhigh-margin potential and sets the stage for significant U.S. scaling in 2026.\nWith over 750,000 patient visits powered by our technology to date in Canada,\nwe have built a proven blueprint that is now positioned for\nU.S.expansion.” \n\nDr. Hamza further added: “Looking ahead through 2026, we have established a\npowerful foundation to build upon, specifically as we accelerate our growth\nstrategy in the United States. Our primary objective is the pursuit of\nhigh-margin opportunities and the expansion of our US payer partnership\nportfolio. By executing on our 'Trojan Horse' strategy, including utilizing\nour infrastructure for white-labeling and federal research programs, we are\nfocused on driving operational efficiency that translates into long-term value\nfor our physicians, patients, and shareholders.”\n\nFiscal 2025 and Fourth Quarter 2025 Annual Financial Highlights:\n* Rocket Doctor AI Inc. achieved record annual revenue of $1,739,219 million\nin 2025, an increase compared to revenue of $10,990 generated in 2024. This\ngrowth was mainly driven by acquisitions completed over the last twelve months\nand the inclusion of Rocket Doctor Inc. consolidated financial reporting.\n* Revenue for Q4 2025 increased to $697,340, representing a 31.8% growth\nquarter-over-quarter from $529,123 in Q3 2025, and 36.1% growth from Q2 2025\nrevenue of $512,755. The continued sequential growth reflects the successful\nintegration of Rocket Doctor Inc., acquired in Q2 2025, and the Company’s\nability to scale its digital healthcare platform. Growth during the period was\ndriven by:  * Increased patient visit volumes across the platform;\n* Expansion of the physician network and service coverage;\n* Improved monetization through patient support fees and subscription revenue;\nand\n* Continued operations scaling following post-acquisition integration.\n  \n* Gross margin for Q4 2025 remained strong at 84%, compared to 88% in Q3 2025\nand 89% in Q2 2025. The modest compression reflects a shift in revenue mix\nfollowing the acquisition of Rocket Doctor Inc., as the Company scaled its\ndigital health platform and marketplace, resulting in higher variable costs\nassociated with increased patient activity.\n* Net comprehensive loss attributable to equity holders of the Company in Q4\nwas $7.3 million or $0.10 per share, compared to $3.5 million or $0.05 in Q3\nand $2.7 million or $0.04 per share in Q2 2025.\n* Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization\n(“Adjusted EBITDA”) was a loss of $2.1 million compared to a loss of $1.8\nmillion in Q3 2025, and a loss of $1.7 million in Q2 2025. The Adjusted EBITDA\ncalculation adjusts for share-based compensation, costs related to\nacquisitions and financings, and change in fair value of contingent\nconsideration. Adjusted EBITDA is used by management to evaluate the\nCompany’s cash operating performance, and a complete definition and\ncalculation are provided further below.\n* Cash and cash equivalents were $641,779 as at December 31, 2025, compared to\n$1.89 million as at September 30, 2025, and $117,595 at June 30, 2025.\nFourth Quarter 2025 Business Highlights: \n\nOn October 8\n(https://www.globenewswire.com/Tracker?data=OH6-weuf8ohY5Q5jb3duI-1zMuSJ-2PMa1ds-pqzYvVftuctYA4ea7NkVV_czFOXW6cR4dVO4UawtT4b_98B-FJKN88nIWtdjVWunk7qIPsCeSsBABp5abKG5257lSYKJyHg3yXuwqhKblFcPp2vAgMI7GQYxFiaYloAr32ONT9uDnBaT0W_issAnUH0d8J6S2PBIszl4FYcQlzdQGzKb7t7qlQdcgqSboiVRWgtMCgiKv7FJjjeAWnYLmnwQ5lE1_Yd8XKTtk2ulBXy7lv9cw==)\nand October 21, 2025\n(https://www.globenewswire.com/Tracker?data=OH6-weuf8ohY5Q5jb3duI25dojSHlI3SfsLpKdgTOxSyW5kzt7bt1kpeGM338KZMr_GTO6cbDtMIczXT23pQVEjttlXmELr9xg-uuDcPyExzdBPnHIeXjA2vJhU8nvs3sS_SLbqjv3-mJ2PfxL-mlyI32f0J-BdrYIwt13FrK-FsHn4I7IPg19YXNHesUu9gnLXg1YjnJKSLAE5E9yQOF3MwrtRWGAPmtYOrpt6o2dRjEg3E2eG5pJh97ifbSqVwJwe2s8JNg0f4xWgJMXv0HQswZdwtA3HmTbuN20G4H1JXxHqJ1ZfrjtOIOPwG_OiDYnbrBd83uwCTDGBzJt8MVQ==),\nthe Company announced multiple in-network agreements with leading U.S.\nhealthcare payers, expanding access to Rocket Doctor’s AI-powered,\nphysician-led digital health platform and marketplace to more than 13 million\ncovered lives across California and New York. These agreements included over\n6.5 million newly added members and extended coverage across commercial,\nMedicare Advantage, and Veterans populations, significantly accelerating the\nCompany’s U.S. expansion strategy.\n\nOn October 15, 2025, the Company announced\n(https://www.globenewswire.com/Tracker?data=N2Q3LlypVU0bobJn7EnJM-UGIyb4Pdk3bTPM7K4pAT0yogOp8aVJtsH0S2ZGcEOKAav1Qfo1CXa_E8fs5MjVKs_wWkR939wywQ6STp3VnIiTWz8JMkVhJ6nv_Zw98KjmHk6ry2BG2Ep9AneoEu-EBC63QY2y9S_fyKoa2FFhXUrZtHcVGh8rIKwJDzHLa5bGNyhrmuPmFDE7bS5OJVWRoF-GBXPM4uHHma73GlmCUHw=)\nit had been awarded over US $500,000 as part of a US$2 million Small Business\nInnovation Research (SBIR) grant from the U.S. National Institutes of Health\n(NIH) to advance its AI-driven medical history collection technology,\nreinforcing its leadership in clinical AI innovation.\n\nOn November 5, 2025, the Company announced\n(https://www.globenewswire.com/Tracker?data=N2Q3LlypVU0bobJn7EnJM-UGIyb4Pdk3bTPM7K4pAT0Od6UnlALCuEeT_2sn0AvIfkdXX6OwEmx1WgHp7y7X4EC1DExiYrQTJdzjW6aebKfGdt2MunFyTUV8eIe-oojkCsMV2Jq8qeppfguzGnW0eQ==)\nfour key leadership appointments to strengthen its U.S. operations, supporting\ncontinued geographic expansion and scaling of its digital health platform.\n\nOn November 19, 2025, the Company announced\n(https://www.globenewswire.com/Tracker?data=N2Q3LlypVU0bobJn7EnJM-UGIyb4Pdk3bTPM7K4pAT2U7YMfJD1H-veru8qewNfP5sBvbCAyhTEtk4sfvk_5mu9dJXfPgU6w6f4sw-moMxHsxPb5l_nLhnE6YvgejA3B0S6IN8lq1nm1swVQRuQm7AlImSAQQFb0VpyIGt-Ppp2U2etOqEsfLYIMCBeHFvNp-PuRUBhgpD4Je9RebE3ligtHrmsDcHiREyAjHDfUsKE=)\nit had entered into a definitive agreement to acquire Alea Health Holdings\nLtd., a conversational AI-powered mental health platform. The acquisition\nexpands Rocket Doctor AI’s capabilities in mental health, enhances its\nGlobal Library of Medicine, and establishes a strategic entry point into the\nMiddle East, including the UAE.\n\nOn November 26, 2025, Rocket Doctor was selected\n(https://www.globenewswire.com/Tracker?data=XHI0Lf4ATXvoKHkbSzybZa5iw_Y1ut6sqMGbh3qnUUnWhGbfzU-Uw6lyuHF9IbiW5pudsj9vqXrlTaanmHEoiPds-O2LnLAZg17eBKiR8RWlEFq06YhWlsvHMb9tHDb2ODKgw2thE4mxH6itA0YjPN-povplrap7Qiy6zAzejeL2JSdscQenw54-MWvHrmLj6AcvJV_I7gHFgJIve6SGuYg6eO4hf5q814gLIin5cV-CUvZdys0JQXwpYLeVTZoFxGwZiLcbX3dWDvOEtKOQBg==)\nto present at the Google Accelerator Alumni event and Heal.LA Demo Day,\nhighlighting the Company’s growing recognition within global digital health\nand AI innovation ecosystems.\n\nOn December 8, 2025, the Company announced\n(https://www.globenewswire.com/Tracker?data=N2Q3LlypVU0bobJn7EnJM-UGIyb4Pdk3bTPM7K4pAT0cGWayPq3mmtd2H4PZgkglRTkj7P3Kv5D3sP9S0hQl1SdK4lDC0-ArmX-3tX_257m6FbVjxA4XOP6uWHr-UZhKUNPu8nAJPHjjCDLEf0iEMh0NZzfD3R5Fq05_-FeX6IcIlYeTkSbjEkdqOwH3RAJdtisUWP08280CCJLvIM1zXh4ZHbZZi2TFdp6XInZd2dfqGRlmuxj3dGAcm1XtrPDlnJ55J4eCV0oUxjdYttAZ7Q==)\na partnership with Health Cities and the CAN Health Network to deploy and\nevaluate its AI-powered clinical decision support tools across primary care\nclinics in Alberta, advancing adoption of its technology within the Canadian\nhealthcare system.\n\nBusiness Highlights Subsequent to December 31, 2025:\n\nOn January 8, 2026, the Company announced\n(https://www.globenewswire.com/Tracker?data=N2Q3LlypVU0bobJn7EnJM-UGIyb4Pdk3bTPM7K4pAT0bs0RKMYzVqY6fQ8lq8qLZlzm_ZR5M53y9DLwHCsY1GR5opYUJA_ROpeU0fbZWU-TFcbqivz3732PY9dnI6LGx0wixt55uFHELibhk9L467BhCrf-5oQdUfic4CalY1bWKtZhiAVavI536u9c1Tx0QbJIhKDh9bkpYSlHWp7NBp4vemiO0gwmIZ-3cLTl2U5i-rbjiswhvuepiwI9mdww_)\nthe completion of its acquisition of Alea Health Holdings Ltd., a\nconversational AI-powered mental health platform. The acquisition enhances\nRocket Doctor AI’s clinical capabilities, expands its Global Library of\nMedicine, and strengthens its position in AI-driven mental health solutions.\n\nOn January 9, 2026, the Company announced\n(https://www.globenewswire.com/Tracker?data=N2Q3LlypVU0bobJn7EnJM-UGIyb4Pdk3bTPM7K4pAT39dWF75yl1V29AgpB8x3LuD7hzh4Ou69ccgmxzYRzbJiYjtN085W9whxD-Ry8eJlKwtXJ77Sc7ABbio2MnUc9CVOgnANx28hBCeKjJ0QI9_xowrwwaKU7SwUEW5SS7lBHNln8p3Oy1_n9yVMmBtJ-3hsK2hNuPWAzgoDZeJE5iHKQFWf_1Ki-SkFn8mTJmkMl4iBAzkDgGeaGJhQOezAJq)\na non-brokered private placement offering under the Listed Issuer Financing\nExemption (“LIFE”). Due to strong investor demand, the financing was\nsubsequently upsized and successfully closed on January 22, 2026\n(https://www.globenewswire.com/Tracker?data=B9T_-_SjhkV_blcRvnuJdrLc3VnO0XddPDw6ozN0S-Zp_ueW-dgDBcRePmHK6ErPQFY2R2QqpZ2NG8U4sx2YqBDklg2hypwXzCk-rh2t1PFZLOxgvWmVYaMY8ezmvFHSsYGOhWZLA5seZEbizBbYB0q2GiLzSdbJFCogRBmGHo6ARBZCit8Baxog4U4ZEf-3pSVXaj0XctGT4rPvBIeXa5lyikf6Mv7Xc-jwFtUJXd5IkPJ0o8FfsBVE9WDm1v8sSr5rm5fbEZIihOUZRFM_eA==),\nfor aggregate gross proceeds of approximately $5.2 million. The Company\nintends to use the proceeds to support continued U.S. expansion, product\ndevelopment, and working capital.\n\nOn February 24, 2026, the Company announced\n(https://www.globenewswire.com/Tracker?data=N2Q3LlypVU0bobJn7EnJM-UGIyb4Pdk3bTPM7K4pAT2EjvtZ-OR7yTLpP2cWsRQlNFKKmvINynj5HSy95Tnqi76iA8qVKP_tCJ7wnAabwaHly5YeDw-7mherbmCDbGgpZD93gg3Tt0xEMOAB3y5QIeLWmuKI8sZuKSRFl2V4Wg1dwSCP584Z5K6R3uyf0FudCEawL4m0sgbRm4HzBOkMAcKR_9vaK3Lx_f6OPfbt_LW5nKkTlaJLto4KrQsGMryuRfGIRCzd4KMuK0L40u8kvzj3r3t7_yxosVvm8hzJKqE=)\na partnership with Lethbridge County to expand access to primary and urgent\ncare services for rural and underserved communities, reinforcing its\ncommitment to improving healthcare accessibility across Canada.\n\nDuring the quarter, the Company expanded its U.S. payer network through\nmultiple in-network agreements with leading insurers across California and New\nYork, adding more than 4.6 million additional covered lives, including\nMedicare Advantage populations, and further strengthening its presence in key\nstrategic markets. These agreements include ~2.2 million members in California\nand ~2.4 million members in New York State, including an additional Medicare\nAdvantage agreement\n(https://www.globenewswire.com/Tracker?data=3Psv52MLNfsySG0v-7eF_F11dz5t7Ww9gXQLeJs5xB9VQ4BqgvJUAB97lMDr8ZSDhK-DOYPxsce_NfZkwqY3me3KRdzizVgZXkBWBPeKlKmjPd7QHEX2mXpyjQ-O491a2h7ZuZaUhTJ4CECAo_0syIikaVKdbG1GSrgV7-g2E9wH9d4iLZonww-Yqo_B1cMQoVZAQRjERG3GUElOpsWYXQTI-03kmF-GB-SjrzzqfamI0lNH9X4Tq1v-tuE_9m5e-N0FsQXmSgq8kJeom7ETMA==).\n(1)\n(https://www.globenewswire.com/Tracker?data=NHnDMdrd4DcAgqp6i8-ZdaUkWdzUfCpUdGiwXi23RjVg5Kax4M53xz6z3vjtFHjBk5v4I03IJooduBnpH_qd5-tsU3h9LtwmWkGNXsyz4i4LQJLenMMhpFUNAGS0y8XW5VYD0rlapEfXRbneMlRjAmIehJGs7SYlMu86qeB7HXPFrkbf7UFtLN3Q-JyKv3NVbPENONjn-D_uMtkHVF-RZ4Yjuih637Yq_4a9QxmJMqm3W_E4aoXfQzBvCpCtlqyp)\n(2)\n(https://www.globenewswire.com/Tracker?data=qefjo1gOc5DarO-ZEoRKvEPr96DDTJYhnTJHk6hTAcpsjsd_fKORoQqHd-6Axxv1TFwpAQy9IctMcOc0QyxrIKdXJVZWSMO-VymKbcioEAvvMhrX9EiXj8nMQwNvi5gZY7FywfTqPws6VgqpdFUvSJt3-RJVKgtZKMKFqfrTeJ-Y9lOQk6i_v1HLehYNqJhBfxTp1Jm1MV0UFGL9ad-IU2fyf2V_1lzesAART3Js64G-9jDul6GpNMfScYMbglvW)\n(3)\n(https://www.globenewswire.com/Tracker?data=Zpyky3ZsuPvLQCdHP9UeS7WzwJk7nPT9PzU148zPJqBxSLGK8XsDfhbY8hgiNqF7QVc0huENeQb9YRkdtqIV9sMeQ2LfeOiI26Ibk7NV9VaLhr75X3-DWXA5XoNswdbKFKCa4ltJpY5slhA78y3kfGv9apVmF5Si00yNsE-2HrUVoYjzWsXTzwGMItF-HMNNebDCJ24oslmsg6OyL103X_Ot9LFGq4_pixk2L91c0tOuBGuCrZiK0_9_C44AFqr8)\n\nThe Company also entered the Maryland market, launching patient care\noperations following the establishment of in-network Medicaid and Medicare\ncoverage and appointing Dr. Suzanne Caccamese as Maryland Medical Lead\n(https://www.globenewswire.com/Tracker?data=AtUZKvCq9FS50adaGAyMpo8sdAK8aqNTgupsCbobwstmndgtOoVpd1eqUSdo6My8As7QX_DMfDkn7iRLAL_B2gv-y1j9BG97KPJwyOopHtndZQ3YHhsGVgJK0Ar4xH0_qaF8j0vyqLbfG-i7PzXq5voT19kBJJXbLgg6BbcShpBvJ2-0rfRBf8rRTj8Zo9mUnE5CMs9zfxYqy08x_hIpgr0Cwh0CaGzAj0LTyfkYWjaRh-bSoGjw5eBvQyhEIOuvUmI4785qv9n2kkj5WtWWkA==).\nThe Company further strengthened its presence through multiple in-network\nagreements with national insurers, adding approximately\n(https://www.globenewswire.com/Tracker?data=oH87F3HivsKPBfm_FwUP1tnUdzClSuuviYoYLD0DiyHgQV6q2flZaLFI-s6J3FOBs1tlkPpQSaLjoG6kSPL4m8Q34o7rl3bqDRJiRMJHT5LZofhCyAp60xrMwQ5inwFGqFlXeGsQhgzriYOxUEZVd8EJpsn6p21sQHD2aIKLXEThW48G6YXfxUTx2e-apiJIFKItVcIVTjgKwvJXJ3vsfWHIhLNLxXps0pjJptc5xWIY-qstWwsd0r30oIPAtDVH4sELKi52etjza3yDYG5pJmn7MHPCUUwKtRcyC0ixC94AWMmngpMVE3IFoR0wnqvx)2.25\nmillion covered lives\n(https://www.globenewswire.com/Tracker?data=XAbA06lShz48iUY5a7MzgQsi-ZS9hPhYbBGV5EWZWwq3nZO0o4w6_3Cx3rB2cfFvg7x-ktZO4pjBYaXVIOuZSm83qs8JmJUNOQ7ISIhV6a_ZAiJnMyzw0v38GYc6nKg2G9_-7sG8bYINtQarbUeseN75lCAgLuB0TDGzsqtjjLVSA8Y7TN3qJa3D11GN_IY2Le0H-jkczFlvg2eYyRpIh_F7LLMk0DiysSO4OihllPTequgTKWWA8D1nVEl31rUzkM-wLspXCOC43VkRFKcXk3RI2MQBe4GYqQxIBQelUqJu7r6xzKKE1U1zvuRPWIJ_WjEAbyC1KJEab_19lsXpOA==),\nincluding an initial agreement with the Maryland state entity of a major\nnational payer and a subsequent expansion of ~250,000 members\n(https://www.globenewswire.com/Tracker?data=8FH0R18rUSSq0U3czWDbTh1CGM11lL8zA49oij7a9W_yWw4LuizdcGLhaXrWvXjvNxwKRdAI1-WO0LJmkhFCmQ_B5puwxDCZFr7MHS0Z8DmuW-f3F03pOIFUY9QNoTqlsZ6Yhv3YrX8uzsDEdwDpMijOb6SO8YqNE34or6c7LKHTT_NjOmIr2oLPc40Y7kwWQ-yEtkSXzY5gWWHgRMiE_OHaktGk2QAZnCDwvT6EZTtp1xiT_xjhZST6XLFdVdbn0pbryOt508X7DO6CNSWA8g==),\nbringing total coverage in the state to approximately 3.2 million covered\nlives.\n\nDuring the quarter, the Company announced approximately $2.05 million in\ngross proceeds\n(https://www.globenewswire.com/Tracker?data=h09xssjLyIgo-3FEo8rzIQeF1BUIgpF5JFmIorj83MU0SnwFjqZbxEsQUSrAm3b2hsCav2IsZ5jcPdJ3lpI_4FkpWPLXGF0dO8GsbOsAOjjw5pl5POHCn40gjjxEcGu2j-w19Sa1E0mFx7w9tQP1FRTj5fC6oWkwBw-uSiU9mZ5QR2URg3AF_0tpgJWxRPgd6OP7yZGe4AAdswXcFWWTHZ1eQbxbkUx1A-bcUlzd1JE=)\nfrom the exercise of warrants and continued to invest in organizational\ngrowth, including the appointment of senior product and engineering leadership\n(https://www.globenewswire.com/Tracker?data=ZY5lRSyBszFpjsvMnuWeyfmLiHAn7A01m9GsOysYCQFPAANDw9vxUI7JY1rd_m_vXOxKRV-YulmYT5eCWpUhG0XiVMt2vQVxibARLj5stwiXTk-liAB_bzwo78ZqjdXTCaQ3oYOoobcideymLQfU1FlemY6rM2I0Sx6QCMmweDSx3EENumxt9NjIOVTO3avafvYWUJgX3Dn96JHI16fickmhl4TCwoMFqfbrkXdkQKgldQExMbbYOJ1MSC8hOurrILpQIli2kJmKPwcYFmPXlw==)\nto support ongoing platform innovation and scalability.\n\nCompany Outlook: \n\nThe Company has seen strong quarter over quarter performance for Q4 over Q3,\nwith an increase in revenues of more than 30%. This is also reflected in the\nyear-on-year revenue growth from 2024 to 2025, driven by the acquisition of\nRocket Doctor Inc. and the announcement of key partnerships during the year.\n\nThe Company is expecting strong operational performance to continue into 2026\nwith an emphasis on increasing US patient visits, emanating from the recently\nannounced payer agreements in California, New York and Maryland. This is\ndriven by the Company now having access to ~21 million “in-network”\npatients, with less than 3% of the associated revenues included in the 2025\nfinancials.\n\nThe Company remains committed to scaling its ecosystem by aggressively growing\nits physician network and patient marketplace across North America. Building\non the momentum of Q4 2025 and Q1 2026, the Company is prioritizing the\nexpansion of its payer partnership portfolio, both through new clients and the\ndeepening of existing relationships. While maintaining a strong operational\nfoundation in its three core States, the Company has begun executing a\nmulti-state expansion strategy to broaden its clinical footprint throughout\nthe remainder of 2026.\n\nFurthermore, the Company is actively pursuing strategic partnerships to\nwhite-label its digital health platform, providing a scalable pathway for U.S.\norganizations to deploy physician-led virtual care under their own established\nbrands.\n\nOperationally, the Company is focused on the continued integration of AI and\nautomation across its core platforms. These enhancements are designed to\noptimize clinical workflows, drive internal efficiencies, and support the\nCompany’s objective of long-term margin expansion.\n\nThe Company continues to advance its partnership with Rush River Research\nunder a US$2 million NIH grant\n(https://www.globenewswire.com/Tracker?data=yxrEmtLldzSHgAOlZwC9o_i35Ywr88TVp0ifmUXnCRkadQtXcIfYIjpvCh7WD9qNmz20pWnmJqXo1mgCLWNm-Yd_OxrGerBj0qsFA8FgzwrJBoD_dtdxrvvVwhNP2IlLhAmKCLq9pTE2LY2wh15nFdXMv3SuodeTDmFgYMOPIHtn5-u2vCTxYnNaiULujEAOCT40BifeXNUIMvkxwVyHpj2puJ-4DzY32zzZEc7M70E=)\ndesigned to transform the collection of family medical histories. By\nleveraging Rocket Doctor’s proprietary AI, the program focuses on developing\nculturally sensitive diagnostic tools that bridge critical gaps in clinical\ndata. This high-impact initiative remains a key operational focus through\n2026, further validating the Company’s ability to secure federal research\nfunding for its clinical reasoning engines.\n\nSelected Audited Financial Highlights:\n\nPlease see SEDAR for complete copies of the Company’s audited annual\nconsolidated financial statements and annual MD&A for the year ended December\n31, 2025.\n\n(https://www.globenewswire.com/Tracker?data=cV3Df-N1AYKow9GOxJrENaEwrlnMmTh8y3y6_5GI3nF2D6YkjIoxprWl6d-PsQGTjB86_g9UoD35oS0jqBg6ll244ascZRm-ZBvbis0K5vy4dRNtL4Fjk2Fi1ZOMmOoPg0XZ_Vkn346BEfvdGnSH6g==)\n\n1)   Gross profit is a non-GAAP measure as described in the Non-GAAP\nFinancial Measures section of this News Release.\n\nClick here to view image\n(https://www.globenewswire.com/Tracker?data=R-pu9t4Ea3ShMoRug_28IiqdmUZ_cxnTIRwzQWzdWxLEy4OY82EfUXcqdy3S3xF95AvewUFONpAMy_-Pauxy6uOwvpqlQJQ6eFsYQsdz6cGqkwUm-we2m7e52bjwYV56cl_B8ap9Re7b_cmiaN_hpkYtuBVMtVH4T-2CDBmTj636RVGGaIqtlQjQ8QTamOdX)\n\n(https://www.globenewswire.com/Tracker?data=vhZR-qGX9JIhKn-QRzJSq_KuNn5u4bxIwCnhFDYu0P9n08Gi7oh4dE6YG0Dl1CqG9zoK9rfDGvyNbOWGe2gNdoxN266dbNjFKXbSihTbBG3bHqllRuviIOiJUtC19V75VzzSQ2YjSQ78oDFX0iYzKA==)\n\n2)  EBITDA and Adjusted EBITDA are non-GAAP measures as described in the\nNon-GAAP Financial Measures section of this News Release.\n\nClick here to view image\n(https://www.globenewswire.com/Tracker?data=R-pu9t4Ea3ShMoRug_28IiqdmUZ_cxnTIRwzQWzdWxLqdS2wTwCYJKmJBJeBae_Lpb432luUCOAZyKJ156bMb_bKLH3x9orhx3kUw6csWFijpCSHycJHwrtBCBpvYOL_kFMlyoi-9y-V-GZA_cDQOcq2sHCDktZJfhtn33RktXBGxL0bjDb1b_bx4skfbdog)\n\nFootnotes:\n\nFinancial Statements and Management’s Discussion and Analysis\n\nThis news release should be read in conjunction with the Company’s condensed\ninterim consolidated financial statements and related notes, and\nmanagement’s discussion and analysis for the three and twelve months ended\nDecember 31, 2025, copies of which can be found at www.sedarplus.ca.\n\nNon-GAAP Financial Measures\n\nIn addition to the results reported in accordance with IFRS, the Company uses\nvarious non-GAAP financial measures and ratios which are not recognized under\nIFRS, as supplemental indicators of the Company’s operating performance and\nfinancial position. These non-GAAP financial measures and ratios are provided\nto enhance the user’s understanding of the Company’s historical and\ncurrent financial performance and its prospects for the future. Management\nbelieves that these measures provide useful information in that they exclude\namounts that are not indicative of the Company’s core operating results and\nongoing operations and provide a more consistent basis for comparison between\nquarters and years. Details of such non-GAAP financial measures and ratios and\nhow they are derived are provided below as well as in conjunction with the\ndiscussion of the financial information reported.\nSince non-GAAP financial measures do not have any standardized meanings\nprescribed by IFRS, other companies may calculate these non-IFRS measures\ndifferently, and our non-GAAP financial measures may not be comparable to\nsimilar titled measures of other companies. Accordingly, investors are\ncautioned not to place undue reliance on them and are also urged to read all\nIFRS accounting disclosures presented in the audited consolidated financial\nstatements and the related notes for the year ended December 31, 2025.\n\nEBITDA\n\nEBITDA is a non-GAAP financial measure that does not have a standard meaning\nand may not be comparable to a similar measure disclosed by other issuers.\nEBITDA referenced herein relates to earnings before interest, taxes,\nimpairment, and depreciation and amortization. This measure does not have a\ncomparable IFRS measure and is used by the Company to assess its capacity to\ngenerate profit from operations before taking into account management’s\nfinancing decisions and costs of consuming intangible and tangible capital\nassets, which vary according to their vintage, technological currency, and\nmanagement’s estimate of their useful life.\n\nAdjusted EBITDA\n\nAdjusted EBITDA is a non-GAAP financial measure that does not have a standard\nmeaning and may not be comparable to a similar measure disclosed by other\nissuers. Adjusted EBITDA referenced herein relates to earnings before\ninterest; taxes; depreciation; amortization; share-based compensation;\nfinancing-related costs; acquisition-related and integration costs, net;\nlitigation costs; and change in fair value of contingent consideration. This\nmeasure does not have a comparable IFRS measure and is used by the Company to\nassess its capacity to generate profit from operations before taking into\naccount management’s financing decisions and costs of consuming intangible\nand tangible capital assets, which vary according to their vintage,\ntechnological currency, and management’s estimate of their useful life,\nadjusted for factors that are unusual in nature or factors that are not\nindicative of the operating performance of the Company.\n\nGross Profit\n\nGross Profit is a non-GAAP financial measure that does not have a standard\nmeaning and may not be comparable to a similar measure disclosed by other\nissuers. Gross Profit referenced herein relates to revenues less cost sales.\nThis measure does not have a comparable IFRS measure and is used by the\nCompany to manage and evaluate the operating performance of the business.\n\nGross Margin\n\nGross Margin is a non-GAAP financial ratio that has Gross Profit, which is a\nnon-GAAP financial measure as a component. Gross Margin referenced herein is\ndefined as gross profit as a percent of total revenue. This measure does not\nhave a comparable IFRS measure and is used by the Company to manage and\nevaluate the operating performance of the business.\n\nAbout Rocket Doctor AI Inc. \n\nRocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed\nto make high-quality healthcare accessible throughout the entire patient\njourney. A cornerstone of the company’s proprietary technology is the Global\nLibrary of Medicine (GLM), a clinically validated decision support system\ndeveloped with input from hundreds of physicians worldwide.\n\nAlongside the GLM is Rocket Doctor Inc, and its AI-powered digital health\nplatform and marketplace. Having helped empower over 350 MDs to provide care\nto more than 750,000 patient visits, our proprietary technology software and\nsystems enable doctors to independently launch and manage their own virtual or\nhybrid in-person practices - improving efficiency, restoring autonomy to MDs,\nand expanding patient access to care. \n\nBy reducing administrative burdens and ensuring greater consistency in care,\nour technology creates more time for meaningful physician-patient\ninteractions. We are committed to reaching underserved, rural, and remote\ncommunities in Canada who often lack access to family doctors and supporting\npatients on Medicaid and Medicare in the United States. With advanced AI,\nlarge language models, and connected medical devices, Rocket Doctor AI is\nredefining modern healthcare - making it more scalable, equitable, and\npatient-centered.\n\nTo learn more about Rocket Doctor AI Inc’s products and services, contact:\n\nwww.rocketdoctor.ai  or email: info@rocketdoctor.ai \n\nFOR ADDITIONAL INFORMATION, CONTACT:\n\nDr. Essam Hamza, CEO, Rocket Doctor AI\nessam.hamza@rocketdoctor.ai \n\nFor media inquiries, contact: media@rocketdoctor.ai \nCall: +1 (778) 819 8321\n\nCautionary Statements\n\nThis news release contains forward-looking statements relating to the future\noperations of Rocket Doctor AI Inc. and other statements that are not\nhistorical facts. Forward-looking statements are often identified by terms\nsuch as \"will,\" \"may,\" \"should,\" \"anticipate,\" \"expects,\" \"intends,\" \"plans,\"\n\"believes,\" \"estimates,\" \"projects,\" \"forecasts,\" \"positioned\" and similar\nexpressions. All statements other than statements of historical fact included\nin this release are forward-looking statements, including, without limitation,\nstatements regarding: the Company's expectation of strong operational\nperformance continuing into 2026; the anticipated increase in U.S. patient\nvisits emanating from the Company's payer agreements in California, New York,\nand Maryland, and the Company's ability to monetize its access to\napproximately 21 million in-network patients; the Company's strategy to scale\nits physician network and patient marketplace across North America; the\nCompany's intention to prioritize the expansion of its payer partnership\nportfolio, both through new clients and the deepening of existing\nrelationships; the Company's multi-state expansion strategy and the broadening\nof its clinical footprint throughout the remainder of 2026; the Company's\npursuit of strategic partnerships to white-label its digital health platform\nand the scalability of that pathway; the Company's integration of AI and\nautomation across its core platforms, and the anticipated optimization of\nclinical workflows, internal efficiencies, and long-term margin expansion; the\nadvancement of the Company's partnership with Rush River Research under the\nUS$2 million NIH grant, and the expected impact of that program through 2026;\nthe successful integration of Alea Health Holdings Ltd. and the anticipated\nenhancement of the Company's clinical capabilities, Global Library of\nMedicine, and position in AI-driven mental health solutions; and  the\nCompany's use of proceeds from its private placement financing to support U.S.\nexpansion, product development, and working capital.\n\nSuch forward-looking statements involve known and unknown risks,\nuncertainties, and other factors that may cause the actual results,\nperformance, or achievements of the Company to be materially different from\nany future results, performances, or achievements expressed or implied by such\nforward-looking statements. There can be no assurance that such statements\nwill prove to be accurate. Important factors that could cause actual results\nto differ materially from the Company's expectations include, but are not\nlimited to: the Company's ability to successfully grow and monetize its U.S.\npayer relationships; competition in the digital healthcare and telehealth\nmarkets; the Company's ability to attract and retain physicians and patients\non its platform; regulatory risks in the healthcare industry in Canada and the\nUnited States; reliance on third-party payers and partners; the Company's\nability to successfully integrate acquired businesses, including Alea Health\nHoldings Ltd.; the Company's ability to continue to secure research funding\nand execute on federal grant programs; general economic conditions; and other\nrisks detailed from time to time in the filings made by Rocket Doctor AI Inc.\nwith securities regulators.\n\nThe reader is cautioned that assumptions used in the preparation of any\nforward-looking information may prove to be incorrect. Events or circumstances\nmay cause actual results to differ materially from those predicted, as a\nresult of numerous known and unknown risks, uncertainties, and other factors,\nmany of which are beyond the control of Rocket Doctor AI Inc. The reader is\ncautioned not to place undue reliance on any forward-looking information. Such\ninformation, although considered reasonable by management at the time of\npreparation, may prove to be incorrect and actual results may differ\nmaterially from those anticipated. Forward-looking statements contained in\nthis news release are expressly qualified by this cautionary statement. The\nforward-looking statements contained in this news release are made as of the\ndate of this news release and Rocket Doctor AI Inc. will only update or revise\npublicly the included forward-looking statements as expressly required by\nCanadian securities law.","article_body_html":"","raw_payload":{"data":{"id":"nGNEbQSGzm","title":"Rocket Doctor AI Reports Strong 2025 Results, Validating Physician-Led Model with Key U.S. Payer Contracts and AI Innovation","author":"Globe Newswire","ticker":"AIDR","created":"2026-05-04T12:00:00.433Z","tickers":["AIDR"],"exchange":"","article_body":"* Continued organic quarter over quarter revenue growth with growth of over\n30% from Q3 to Q4 2025 (from $529,123 in Q3 2025 to $697,340 for Q4 2025)\n \n*  Earnings per share for Q4, 2025: ($0.10) per share.\n\n\n*  Annual Revenues of $1.739 million in FY2025\n   *  Announced signed in-network contracts and credentialing with several\nmajor U.S. insurance companies. Extending Rocket Doctor’s U.S. total\nin-network reach to over 21 million members.\nVancouver, BC , May 04, 2026 (GLOBE NEWSWIRE) -- Rocket Doctor AI Inc. (CSE:\nAIDR\n(https://www.globenewswire.com/Tracker?data=ZKL6DIwea7jTPl3bzR_Sti7kGX66ydkpvTo4ymZla64iTVmMTnprzDr0y9L7VcgF8h0WUivDJAJTBFnKow1xcOSZbRTwkpd2VrWmLlSnGek=),\nOTC: AIRDF\n(https://www.globenewswire.com/Tracker?data=LQ25uKv4ke4oRoh9LCOKYyC1oPFgnErd7MvwD0LFnkiO2HKqXDtFLwkTrLHAdM3JNLJmi5-9CYsOFZM7GdQ5v0yrvl952Z_C_RsqOTWCwuw=),\nFrankfurt: 939\n(https://www.globenewswire.com/Tracker?data=hmr8FtfLlvjfzMlHUbecVnjVRNXRqpUJv7dcOO8fngFWLGikIipzzvUfVtNpI80DVhZ-Akn8rq2JFIC8BAN7UXk7mOan_fOUkQNfmvJqd2ZoarsARyr14N7Z7Eesqvje))\n(“Rocket Doctor AI” or the “Company”), a physician-built, AI-powered\nhealthcare technology company focused on empowering doctors and expanding\naccess to high-quality care, is pleased to announce that it has filed its\naudited annual financial statements for the fiscal year and fourth quarter\nended December 31, 2025. The Company’s financial statements and\nManagement’s Discussion and Analysis (“MD&A”) are available under its\nprofile on SEDAR+ at www.sedarplus.ca.\n\nDr. Essam Hamza, CEO of Rocket Doctor AI Inc., commented: “2025 was a\nfoundational year for Rocket Doctor AI as we transitioned from proving our\nconcept to demonstrating the potential scalability of our physician-led model.\nFollowing the successful acquisition and integration of Rocket Doctor Inc.\nearlier this year, I am delighted with the significant progress the Company\nhas made. We have successfully shifted our focus toward operational\nexcellence, allowing us to support doctors in reducing administrative\nheadaches and overhead while expanding access to care for the populations that\nneed it most.”\n\nDr. Hamza continued: “The resilience of our marketplace is evidenced by our\n30% quarter-over-quarter organic growth from Q3 to Q4, led primarily by our\nestablished Canadian operations. This momentum is a direct result of our\ntechnological efficiencies and our recent strategic entry into the U.S. payer\nmarket. While U.S. operations represented less than 3% of our 2025 revenue,\nthe recent finalization of key payer agreements validates our infrastructure's\nhigh-margin potential and sets the stage for significant U.S. scaling in 2026.\nWith over 750,000 patient visits powered by our technology to date in Canada,\nwe have built a proven blueprint that is now positioned for\nU.S.expansion.” \n\nDr. Hamza further added: “Looking ahead through 2026, we have established a\npowerful foundation to build upon, specifically as we accelerate our growth\nstrategy in the United States. Our primary objective is the pursuit of\nhigh-margin opportunities and the expansion of our US payer partnership\nportfolio. By executing on our 'Trojan Horse' strategy, including utilizing\nour infrastructure for white-labeling and federal research programs, we are\nfocused on driving operational efficiency that translates into long-term value\nfor our physicians, patients, and shareholders.”\n\nFiscal 2025 and Fourth Quarter 2025 Annual Financial Highlights:\n* Rocket Doctor AI Inc. achieved record annual revenue of $1,739,219 million\nin 2025, an increase compared to revenue of $10,990 generated in 2024. This\ngrowth was mainly driven by acquisitions completed over the last twelve months\nand the inclusion of Rocket Doctor Inc. consolidated financial reporting.\n* Revenue for Q4 2025 increased to $697,340, representing a 31.8% growth\nquarter-over-quarter from $529,123 in Q3 2025, and 36.1% growth from Q2 2025\nrevenue of $512,755. The continued sequential growth reflects the successful\nintegration of Rocket Doctor Inc., acquired in Q2 2025, and the Company’s\nability to scale its digital healthcare platform. Growth during the period was\ndriven by:  * Increased patient visit volumes across the platform;\n* Expansion of the physician network and service coverage;\n* Improved monetization through patient support fees and subscription revenue;\nand\n* Continued operations scaling following post-acquisition integration.\n  \n* Gross margin for Q4 2025 remained strong at 84%, compared to 88% in Q3 2025\nand 89% in Q2 2025. The modest compression reflects a shift in revenue mix\nfollowing the acquisition of Rocket Doctor Inc., as the Company scaled its\ndigital health platform and marketplace, resulting in higher variable costs\nassociated with increased patient activity.\n* Net comprehensive loss attributable to equity holders of the Company in Q4\nwas $7.3 million or $0.10 per share, compared to $3.5 million or $0.05 in Q3\nand $2.7 million or $0.04 per share in Q2 2025.\n* Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization\n(“Adjusted EBITDA”) was a loss of $2.1 million compared to a loss of $1.8\nmillion in Q3 2025, and a loss of $1.7 million in Q2 2025. The Adjusted EBITDA\ncalculation adjusts for share-based compensation, costs related to\nacquisitions and financings, and change in fair value of contingent\nconsideration. Adjusted EBITDA is used by management to evaluate the\nCompany’s cash operating performance, and a complete definition and\ncalculation are provided further below.\n* Cash and cash equivalents were $641,779 as at December 31, 2025, compared to\n$1.89 million as at September 30, 2025, and $117,595 at June 30, 2025.\nFourth Quarter 2025 Business Highlights: \n\nOn October 8\n(https://www.globenewswire.com/Tracker?data=OH6-weuf8ohY5Q5jb3duI-1zMuSJ-2PMa1ds-pqzYvVftuctYA4ea7NkVV_czFOXW6cR4dVO4UawtT4b_98B-FJKN88nIWtdjVWunk7qIPsCeSsBABp5abKG5257lSYKJyHg3yXuwqhKblFcPp2vAgMI7GQYxFiaYloAr32ONT9uDnBaT0W_issAnUH0d8J6S2PBIszl4FYcQlzdQGzKb7t7qlQdcgqSboiVRWgtMCgiKv7FJjjeAWnYLmnwQ5lE1_Yd8XKTtk2ulBXy7lv9cw==)\nand October 21, 2025\n(https://www.globenewswire.com/Tracker?data=OH6-weuf8ohY5Q5jb3duI25dojSHlI3SfsLpKdgTOxSyW5kzt7bt1kpeGM338KZMr_GTO6cbDtMIczXT23pQVEjttlXmELr9xg-uuDcPyExzdBPnHIeXjA2vJhU8nvs3sS_SLbqjv3-mJ2PfxL-mlyI32f0J-BdrYIwt13FrK-FsHn4I7IPg19YXNHesUu9gnLXg1YjnJKSLAE5E9yQOF3MwrtRWGAPmtYOrpt6o2dRjEg3E2eG5pJh97ifbSqVwJwe2s8JNg0f4xWgJMXv0HQswZdwtA3HmTbuN20G4H1JXxHqJ1ZfrjtOIOPwG_OiDYnbrBd83uwCTDGBzJt8MVQ==),\nthe Company announced multiple in-network agreements with leading U.S.\nhealthcare payers, expanding access to Rocket Doctor’s AI-powered,\nphysician-led digital health platform and marketplace to more than 13 million\ncovered lives across California and New York. These agreements included over\n6.5 million newly added members and extended coverage across commercial,\nMedicare Advantage, and Veterans populations, significantly accelerating the\nCompany’s U.S. expansion strategy.\n\nOn October 15, 2025, the Company announced\n(https://www.globenewswire.com/Tracker?data=N2Q3LlypVU0bobJn7EnJM-UGIyb4Pdk3bTPM7K4pAT0yogOp8aVJtsH0S2ZGcEOKAav1Qfo1CXa_E8fs5MjVKs_wWkR939wywQ6STp3VnIiTWz8JMkVhJ6nv_Zw98KjmHk6ry2BG2Ep9AneoEu-EBC63QY2y9S_fyKoa2FFhXUrZtHcVGh8rIKwJDzHLa5bGNyhrmuPmFDE7bS5OJVWRoF-GBXPM4uHHma73GlmCUHw=)\nit had been awarded over US $500,000 as part of a US$2 million Small Business\nInnovation Research (SBIR) grant from the U.S. National Institutes of Health\n(NIH) to advance its AI-driven medical history collection technology,\nreinforcing its leadership in clinical AI innovation.\n\nOn November 5, 2025, the Company announced\n(https://www.globenewswire.com/Tracker?data=N2Q3LlypVU0bobJn7EnJM-UGIyb4Pdk3bTPM7K4pAT0Od6UnlALCuEeT_2sn0AvIfkdXX6OwEmx1WgHp7y7X4EC1DExiYrQTJdzjW6aebKfGdt2MunFyTUV8eIe-oojkCsMV2Jq8qeppfguzGnW0eQ==)\nfour key leadership appointments to strengthen its U.S. operations, supporting\ncontinued geographic expansion and scaling of its digital health platform.\n\nOn November 19, 2025, the Company announced\n(https://www.globenewswire.com/Tracker?data=N2Q3LlypVU0bobJn7EnJM-UGIyb4Pdk3bTPM7K4pAT2U7YMfJD1H-veru8qewNfP5sBvbCAyhTEtk4sfvk_5mu9dJXfPgU6w6f4sw-moMxHsxPb5l_nLhnE6YvgejA3B0S6IN8lq1nm1swVQRuQm7AlImSAQQFb0VpyIGt-Ppp2U2etOqEsfLYIMCBeHFvNp-PuRUBhgpD4Je9RebE3ligtHrmsDcHiREyAjHDfUsKE=)\nit had entered into a definitive agreement to acquire Alea Health Holdings\nLtd., a conversational AI-powered mental health platform. The acquisition\nexpands Rocket Doctor AI’s capabilities in mental health, enhances its\nGlobal Library of Medicine, and establishes a strategic entry point into the\nMiddle East, including the UAE.\n\nOn November 26, 2025, Rocket Doctor was selected\n(https://www.globenewswire.com/Tracker?data=XHI0Lf4ATXvoKHkbSzybZa5iw_Y1ut6sqMGbh3qnUUnWhGbfzU-Uw6lyuHF9IbiW5pudsj9vqXrlTaanmHEoiPds-O2LnLAZg17eBKiR8RWlEFq06YhWlsvHMb9tHDb2ODKgw2thE4mxH6itA0YjPN-povplrap7Qiy6zAzejeL2JSdscQenw54-MWvHrmLj6AcvJV_I7gHFgJIve6SGuYg6eO4hf5q814gLIin5cV-CUvZdys0JQXwpYLeVTZoFxGwZiLcbX3dWDvOEtKOQBg==)\nto present at the Google Accelerator Alumni event and Heal.LA Demo Day,\nhighlighting the Company’s growing recognition within global digital health\nand AI innovation ecosystems.\n\nOn December 8, 2025, the Company announced\n(https://www.globenewswire.com/Tracker?data=N2Q3LlypVU0bobJn7EnJM-UGIyb4Pdk3bTPM7K4pAT0cGWayPq3mmtd2H4PZgkglRTkj7P3Kv5D3sP9S0hQl1SdK4lDC0-ArmX-3tX_257m6FbVjxA4XOP6uWHr-UZhKUNPu8nAJPHjjCDLEf0iEMh0NZzfD3R5Fq05_-FeX6IcIlYeTkSbjEkdqOwH3RAJdtisUWP08280CCJLvIM1zXh4ZHbZZi2TFdp6XInZd2dfqGRlmuxj3dGAcm1XtrPDlnJ55J4eCV0oUxjdYttAZ7Q==)\na partnership with Health Cities and the CAN Health Network to deploy and\nevaluate its AI-powered clinical decision support tools across primary care\nclinics in Alberta, advancing adoption of its technology within the Canadian\nhealthcare system.\n\nBusiness Highlights Subsequent to December 31, 2025:\n\nOn January 8, 2026, the Company announced\n(https://www.globenewswire.com/Tracker?data=N2Q3LlypVU0bobJn7EnJM-UGIyb4Pdk3bTPM7K4pAT0bs0RKMYzVqY6fQ8lq8qLZlzm_ZR5M53y9DLwHCsY1GR5opYUJA_ROpeU0fbZWU-TFcbqivz3732PY9dnI6LGx0wixt55uFHELibhk9L467BhCrf-5oQdUfic4CalY1bWKtZhiAVavI536u9c1Tx0QbJIhKDh9bkpYSlHWp7NBp4vemiO0gwmIZ-3cLTl2U5i-rbjiswhvuepiwI9mdww_)\nthe completion of its acquisition of Alea Health Holdings Ltd., a\nconversational AI-powered mental health platform. The acquisition enhances\nRocket Doctor AI’s clinical capabilities, expands its Global Library of\nMedicine, and strengthens its position in AI-driven mental health solutions.\n\nOn January 9, 2026, the Company announced\n(https://www.globenewswire.com/Tracker?data=N2Q3LlypVU0bobJn7EnJM-UGIyb4Pdk3bTPM7K4pAT39dWF75yl1V29AgpB8x3LuD7hzh4Ou69ccgmxzYRzbJiYjtN085W9whxD-Ry8eJlKwtXJ77Sc7ABbio2MnUc9CVOgnANx28hBCeKjJ0QI9_xowrwwaKU7SwUEW5SS7lBHNln8p3Oy1_n9yVMmBtJ-3hsK2hNuPWAzgoDZeJE5iHKQFWf_1Ki-SkFn8mTJmkMl4iBAzkDgGeaGJhQOezAJq)\na non-brokered private placement offering under the Listed Issuer Financing\nExemption (“LIFE”). Due to strong investor demand, the financing was\nsubsequently upsized and successfully closed on January 22, 2026\n(https://www.globenewswire.com/Tracker?data=B9T_-_SjhkV_blcRvnuJdrLc3VnO0XddPDw6ozN0S-Zp_ueW-dgDBcRePmHK6ErPQFY2R2QqpZ2NG8U4sx2YqBDklg2hypwXzCk-rh2t1PFZLOxgvWmVYaMY8ezmvFHSsYGOhWZLA5seZEbizBbYB0q2GiLzSdbJFCogRBmGHo6ARBZCit8Baxog4U4ZEf-3pSVXaj0XctGT4rPvBIeXa5lyikf6Mv7Xc-jwFtUJXd5IkPJ0o8FfsBVE9WDm1v8sSr5rm5fbEZIihOUZRFM_eA==),\nfor aggregate gross proceeds of approximately $5.2 million. The Company\nintends to use the proceeds to support continued U.S. expansion, product\ndevelopment, and working capital.\n\nOn February 24, 2026, the Company announced\n(https://www.globenewswire.com/Tracker?data=N2Q3LlypVU0bobJn7EnJM-UGIyb4Pdk3bTPM7K4pAT2EjvtZ-OR7yTLpP2cWsRQlNFKKmvINynj5HSy95Tnqi76iA8qVKP_tCJ7wnAabwaHly5YeDw-7mherbmCDbGgpZD93gg3Tt0xEMOAB3y5QIeLWmuKI8sZuKSRFl2V4Wg1dwSCP584Z5K6R3uyf0FudCEawL4m0sgbRm4HzBOkMAcKR_9vaK3Lx_f6OPfbt_LW5nKkTlaJLto4KrQsGMryuRfGIRCzd4KMuK0L40u8kvzj3r3t7_yxosVvm8hzJKqE=)\na partnership with Lethbridge County to expand access to primary and urgent\ncare services for rural and underserved communities, reinforcing its\ncommitment to improving healthcare accessibility across Canada.\n\nDuring the quarter, the Company expanded its U.S. payer network through\nmultiple in-network agreements with leading insurers across California and New\nYork, adding more than 4.6 million additional covered lives, including\nMedicare Advantage populations, and further strengthening its presence in key\nstrategic markets. These agreements include ~2.2 million members in California\nand ~2.4 million members in New York State, including an additional Medicare\nAdvantage agreement\n(https://www.globenewswire.com/Tracker?data=3Psv52MLNfsySG0v-7eF_F11dz5t7Ww9gXQLeJs5xB9VQ4BqgvJUAB97lMDr8ZSDhK-DOYPxsce_NfZkwqY3me3KRdzizVgZXkBWBPeKlKmjPd7QHEX2mXpyjQ-O491a2h7ZuZaUhTJ4CECAo_0syIikaVKdbG1GSrgV7-g2E9wH9d4iLZonww-Yqo_B1cMQoVZAQRjERG3GUElOpsWYXQTI-03kmF-GB-SjrzzqfamI0lNH9X4Tq1v-tuE_9m5e-N0FsQXmSgq8kJeom7ETMA==).\n(1)\n(https://www.globenewswire.com/Tracker?data=NHnDMdrd4DcAgqp6i8-ZdaUkWdzUfCpUdGiwXi23RjVg5Kax4M53xz6z3vjtFHjBk5v4I03IJooduBnpH_qd5-tsU3h9LtwmWkGNXsyz4i4LQJLenMMhpFUNAGS0y8XW5VYD0rlapEfXRbneMlRjAmIehJGs7SYlMu86qeB7HXPFrkbf7UFtLN3Q-JyKv3NVbPENONjn-D_uMtkHVF-RZ4Yjuih637Yq_4a9QxmJMqm3W_E4aoXfQzBvCpCtlqyp)\n(2)\n(https://www.globenewswire.com/Tracker?data=qefjo1gOc5DarO-ZEoRKvEPr96DDTJYhnTJHk6hTAcpsjsd_fKORoQqHd-6Axxv1TFwpAQy9IctMcOc0QyxrIKdXJVZWSMO-VymKbcioEAvvMhrX9EiXj8nMQwNvi5gZY7FywfTqPws6VgqpdFUvSJt3-RJVKgtZKMKFqfrTeJ-Y9lOQk6i_v1HLehYNqJhBfxTp1Jm1MV0UFGL9ad-IU2fyf2V_1lzesAART3Js64G-9jDul6GpNMfScYMbglvW)\n(3)\n(https://www.globenewswire.com/Tracker?data=Zpyky3ZsuPvLQCdHP9UeS7WzwJk7nPT9PzU148zPJqBxSLGK8XsDfhbY8hgiNqF7QVc0huENeQb9YRkdtqIV9sMeQ2LfeOiI26Ibk7NV9VaLhr75X3-DWXA5XoNswdbKFKCa4ltJpY5slhA78y3kfGv9apVmF5Si00yNsE-2HrUVoYjzWsXTzwGMItF-HMNNebDCJ24oslmsg6OyL103X_Ot9LFGq4_pixk2L91c0tOuBGuCrZiK0_9_C44AFqr8)\n\nThe Company also entered the Maryland market, launching patient care\noperations following the establishment of in-network Medicaid and Medicare\ncoverage and appointing Dr. Suzanne Caccamese as Maryland Medical Lead\n(https://www.globenewswire.com/Tracker?data=AtUZKvCq9FS50adaGAyMpo8sdAK8aqNTgupsCbobwstmndgtOoVpd1eqUSdo6My8As7QX_DMfDkn7iRLAL_B2gv-y1j9BG97KPJwyOopHtndZQ3YHhsGVgJK0Ar4xH0_qaF8j0vyqLbfG-i7PzXq5voT19kBJJXbLgg6BbcShpBvJ2-0rfRBf8rRTj8Zo9mUnE5CMs9zfxYqy08x_hIpgr0Cwh0CaGzAj0LTyfkYWjaRh-bSoGjw5eBvQyhEIOuvUmI4785qv9n2kkj5WtWWkA==).\nThe Company further strengthened its presence through multiple in-network\nagreements with national insurers, adding approximately\n(https://www.globenewswire.com/Tracker?data=oH87F3HivsKPBfm_FwUP1tnUdzClSuuviYoYLD0DiyHgQV6q2flZaLFI-s6J3FOBs1tlkPpQSaLjoG6kSPL4m8Q34o7rl3bqDRJiRMJHT5LZofhCyAp60xrMwQ5inwFGqFlXeGsQhgzriYOxUEZVd8EJpsn6p21sQHD2aIKLXEThW48G6YXfxUTx2e-apiJIFKItVcIVTjgKwvJXJ3vsfWHIhLNLxXps0pjJptc5xWIY-qstWwsd0r30oIPAtDVH4sELKi52etjza3yDYG5pJmn7MHPCUUwKtRcyC0ixC94AWMmngpMVE3IFoR0wnqvx)2.25\nmillion covered lives\n(https://www.globenewswire.com/Tracker?data=XAbA06lShz48iUY5a7MzgQsi-ZS9hPhYbBGV5EWZWwq3nZO0o4w6_3Cx3rB2cfFvg7x-ktZO4pjBYaXVIOuZSm83qs8JmJUNOQ7ISIhV6a_ZAiJnMyzw0v38GYc6nKg2G9_-7sG8bYINtQarbUeseN75lCAgLuB0TDGzsqtjjLVSA8Y7TN3qJa3D11GN_IY2Le0H-jkczFlvg2eYyRpIh_F7LLMk0DiysSO4OihllPTequgTKWWA8D1nVEl31rUzkM-wLspXCOC43VkRFKcXk3RI2MQBe4GYqQxIBQelUqJu7r6xzKKE1U1zvuRPWIJ_WjEAbyC1KJEab_19lsXpOA==),\nincluding an initial agreement with the Maryland state entity of a major\nnational payer and a subsequent expansion of ~250,000 members\n(https://www.globenewswire.com/Tracker?data=8FH0R18rUSSq0U3czWDbTh1CGM11lL8zA49oij7a9W_yWw4LuizdcGLhaXrWvXjvNxwKRdAI1-WO0LJmkhFCmQ_B5puwxDCZFr7MHS0Z8DmuW-f3F03pOIFUY9QNoTqlsZ6Yhv3YrX8uzsDEdwDpMijOb6SO8YqNE34or6c7LKHTT_NjOmIr2oLPc40Y7kwWQ-yEtkSXzY5gWWHgRMiE_OHaktGk2QAZnCDwvT6EZTtp1xiT_xjhZST6XLFdVdbn0pbryOt508X7DO6CNSWA8g==),\nbringing total coverage in the state to approximately 3.2 million covered\nlives.\n\nDuring the quarter, the Company announced approximately $2.05 million in\ngross proceeds\n(https://www.globenewswire.com/Tracker?data=h09xssjLyIgo-3FEo8rzIQeF1BUIgpF5JFmIorj83MU0SnwFjqZbxEsQUSrAm3b2hsCav2IsZ5jcPdJ3lpI_4FkpWPLXGF0dO8GsbOsAOjjw5pl5POHCn40gjjxEcGu2j-w19Sa1E0mFx7w9tQP1FRTj5fC6oWkwBw-uSiU9mZ5QR2URg3AF_0tpgJWxRPgd6OP7yZGe4AAdswXcFWWTHZ1eQbxbkUx1A-bcUlzd1JE=)\nfrom the exercise of warrants and continued to invest in organizational\ngrowth, including the appointment of senior product and engineering leadership\n(https://www.globenewswire.com/Tracker?data=ZY5lRSyBszFpjsvMnuWeyfmLiHAn7A01m9GsOysYCQFPAANDw9vxUI7JY1rd_m_vXOxKRV-YulmYT5eCWpUhG0XiVMt2vQVxibARLj5stwiXTk-liAB_bzwo78ZqjdXTCaQ3oYOoobcideymLQfU1FlemY6rM2I0Sx6QCMmweDSx3EENumxt9NjIOVTO3avafvYWUJgX3Dn96JHI16fickmhl4TCwoMFqfbrkXdkQKgldQExMbbYOJ1MSC8hOurrILpQIli2kJmKPwcYFmPXlw==)\nto support ongoing platform innovation and scalability.\n\nCompany Outlook: \n\nThe Company has seen strong quarter over quarter performance for Q4 over Q3,\nwith an increase in revenues of more than 30%. This is also reflected in the\nyear-on-year revenue growth from 2024 to 2025, driven by the acquisition of\nRocket Doctor Inc. and the announcement of key partnerships during the year.\n\nThe Company is expecting strong operational performance to continue into 2026\nwith an emphasis on increasing US patient visits, emanating from the recently\nannounced payer agreements in California, New York and Maryland. This is\ndriven by the Company now having access to ~21 million “in-network”\npatients, with less than 3% of the associated revenues included in the 2025\nfinancials.\n\nThe Company remains committed to scaling its ecosystem by aggressively growing\nits physician network and patient marketplace across North America. Building\non the momentum of Q4 2025 and Q1 2026, the Company is prioritizing the\nexpansion of its payer partnership portfolio, both through new clients and the\ndeepening of existing relationships. While maintaining a strong operational\nfoundation in its three core States, the Company has begun executing a\nmulti-state expansion strategy to broaden its clinical footprint throughout\nthe remainder of 2026.\n\nFurthermore, the Company is actively pursuing strategic partnerships to\nwhite-label its digital health platform, providing a scalable pathway for U.S.\norganizations to deploy physician-led virtual care under their own established\nbrands.\n\nOperationally, the Company is focused on the continued integration of AI and\nautomation across its core platforms. These enhancements are designed to\noptimize clinical workflows, drive internal efficiencies, and support the\nCompany’s objective of long-term margin expansion.\n\nThe Company continues to advance its partnership with Rush River Research\nunder a US$2 million NIH grant\n(https://www.globenewswire.com/Tracker?data=yxrEmtLldzSHgAOlZwC9o_i35Ywr88TVp0ifmUXnCRkadQtXcIfYIjpvCh7WD9qNmz20pWnmJqXo1mgCLWNm-Yd_OxrGerBj0qsFA8FgzwrJBoD_dtdxrvvVwhNP2IlLhAmKCLq9pTE2LY2wh15nFdXMv3SuodeTDmFgYMOPIHtn5-u2vCTxYnNaiULujEAOCT40BifeXNUIMvkxwVyHpj2puJ-4DzY32zzZEc7M70E=)\ndesigned to transform the collection of family medical histories. By\nleveraging Rocket Doctor’s proprietary AI, the program focuses on developing\nculturally sensitive diagnostic tools that bridge critical gaps in clinical\ndata. This high-impact initiative remains a key operational focus through\n2026, further validating the Company’s ability to secure federal research\nfunding for its clinical reasoning engines.\n\nSelected Audited Financial Highlights:\n\nPlease see SEDAR for complete copies of the Company’s audited annual\nconsolidated financial statements and annual MD&A for the year ended December\n31, 2025.\n\n(https://www.globenewswire.com/Tracker?data=cV3Df-N1AYKow9GOxJrENaEwrlnMmTh8y3y6_5GI3nF2D6YkjIoxprWl6d-PsQGTjB86_g9UoD35oS0jqBg6ll244ascZRm-ZBvbis0K5vy4dRNtL4Fjk2Fi1ZOMmOoPg0XZ_Vkn346BEfvdGnSH6g==)\n\n1)   Gross profit is a non-GAAP measure as described in the Non-GAAP\nFinancial Measures section of this News Release.\n\nClick here to view image\n(https://www.globenewswire.com/Tracker?data=R-pu9t4Ea3ShMoRug_28IiqdmUZ_cxnTIRwzQWzdWxLEy4OY82EfUXcqdy3S3xF95AvewUFONpAMy_-Pauxy6uOwvpqlQJQ6eFsYQsdz6cGqkwUm-we2m7e52bjwYV56cl_B8ap9Re7b_cmiaN_hpkYtuBVMtVH4T-2CDBmTj636RVGGaIqtlQjQ8QTamOdX)\n\n(https://www.globenewswire.com/Tracker?data=vhZR-qGX9JIhKn-QRzJSq_KuNn5u4bxIwCnhFDYu0P9n08Gi7oh4dE6YG0Dl1CqG9zoK9rfDGvyNbOWGe2gNdoxN266dbNjFKXbSihTbBG3bHqllRuviIOiJUtC19V75VzzSQ2YjSQ78oDFX0iYzKA==)\n\n2)  EBITDA and Adjusted EBITDA are non-GAAP measures as described in the\nNon-GAAP Financial Measures section of this News Release.\n\nClick here to view image\n(https://www.globenewswire.com/Tracker?data=R-pu9t4Ea3ShMoRug_28IiqdmUZ_cxnTIRwzQWzdWxLqdS2wTwCYJKmJBJeBae_Lpb432luUCOAZyKJ156bMb_bKLH3x9orhx3kUw6csWFijpCSHycJHwrtBCBpvYOL_kFMlyoi-9y-V-GZA_cDQOcq2sHCDktZJfhtn33RktXBGxL0bjDb1b_bx4skfbdog)\n\nFootnotes:\n\nFinancial Statements and Management’s Discussion and Analysis\n\nThis news release should be read in conjunction with the Company’s condensed\ninterim consolidated financial statements and related notes, and\nmanagement’s discussion and analysis for the three and twelve months ended\nDecember 31, 2025, copies of which can be found at www.sedarplus.ca.\n\nNon-GAAP Financial Measures\n\nIn addition to the results reported in accordance with IFRS, the Company uses\nvarious non-GAAP financial measures and ratios which are not recognized under\nIFRS, as supplemental indicators of the Company’s operating performance and\nfinancial position. These non-GAAP financial measures and ratios are provided\nto enhance the user’s understanding of the Company’s historical and\ncurrent financial performance and its prospects for the future. Management\nbelieves that these measures provide useful information in that they exclude\namounts that are not indicative of the Company’s core operating results and\nongoing operations and provide a more consistent basis for comparison between\nquarters and years. Details of such non-GAAP financial measures and ratios and\nhow they are derived are provided below as well as in conjunction with the\ndiscussion of the financial information reported.\nSince non-GAAP financial measures do not have any standardized meanings\nprescribed by IFRS, other companies may calculate these non-IFRS measures\ndifferently, and our non-GAAP financial measures may not be comparable to\nsimilar titled measures of other companies. Accordingly, investors are\ncautioned not to place undue reliance on them and are also urged to read all\nIFRS accounting disclosures presented in the audited consolidated financial\nstatements and the related notes for the year ended December 31, 2025.\n\nEBITDA\n\nEBITDA is a non-GAAP financial measure that does not have a standard meaning\nand may not be comparable to a similar measure disclosed by other issuers.\nEBITDA referenced herein relates to earnings before interest, taxes,\nimpairment, and depreciation and amortization. This measure does not have a\ncomparable IFRS measure and is used by the Company to assess its capacity to\ngenerate profit from operations before taking into account management’s\nfinancing decisions and costs of consuming intangible and tangible capital\nassets, which vary according to their vintage, technological currency, and\nmanagement’s estimate of their useful life.\n\nAdjusted EBITDA\n\nAdjusted EBITDA is a non-GAAP financial measure that does not have a standard\nmeaning and may not be comparable to a similar measure disclosed by other\nissuers. Adjusted EBITDA referenced herein relates to earnings before\ninterest; taxes; depreciation; amortization; share-based compensation;\nfinancing-related costs; acquisition-related and integration costs, net;\nlitigation costs; and change in fair value of contingent consideration. This\nmeasure does not have a comparable IFRS measure and is used by the Company to\nassess its capacity to generate profit from operations before taking into\naccount management’s financing decisions and costs of consuming intangible\nand tangible capital assets, which vary according to their vintage,\ntechnological currency, and management’s estimate of their useful life,\nadjusted for factors that are unusual in nature or factors that are not\nindicative of the operating performance of the Company.\n\nGross Profit\n\nGross Profit is a non-GAAP financial measure that does not have a standard\nmeaning and may not be comparable to a similar measure disclosed by other\nissuers. Gross Profit referenced herein relates to revenues less cost sales.\nThis measure does not have a comparable IFRS measure and is used by the\nCompany to manage and evaluate the operating performance of the business.\n\nGross Margin\n\nGross Margin is a non-GAAP financial ratio that has Gross Profit, which is a\nnon-GAAP financial measure as a component. Gross Margin referenced herein is\ndefined as gross profit as a percent of total revenue. This measure does not\nhave a comparable IFRS measure and is used by the Company to manage and\nevaluate the operating performance of the business.\n\nAbout Rocket Doctor AI Inc. \n\nRocket Doctor AI Inc. delivers physician-built, AI-powered solutions designed\nto make high-quality healthcare accessible throughout the entire patient\njourney. A cornerstone of the company’s proprietary technology is the Global\nLibrary of Medicine (GLM), a clinically validated decision support system\ndeveloped with input from hundreds of physicians worldwide.\n\nAlongside the GLM is Rocket Doctor Inc, and its AI-powered digital health\nplatform and marketplace. Having helped empower over 350 MDs to provide care\nto more than 750,000 patient visits, our proprietary technology software and\nsystems enable doctors to independently launch and manage their own virtual or\nhybrid in-person practices - improving efficiency, restoring autonomy to MDs,\nand expanding patient access to care. \n\nBy reducing administrative burdens and ensuring greater consistency in care,\nour technology creates more time for meaningful physician-patient\ninteractions. We are committed to reaching underserved, rural, and remote\ncommunities in Canada who often lack access to family doctors and supporting\npatients on Medicaid and Medicare in the United States. With advanced AI,\nlarge language models, and connected medical devices, Rocket Doctor AI is\nredefining modern healthcare - making it more scalable, equitable, and\npatient-centered.\n\nTo learn more about Rocket Doctor AI Inc’s products and services, contact:\n\nwww.rocketdoctor.ai  or email: info@rocketdoctor.ai \n\nFOR ADDITIONAL INFORMATION, CONTACT:\n\nDr. Essam Hamza, CEO, Rocket Doctor AI\nessam.hamza@rocketdoctor.ai \n\nFor media inquiries, contact: media@rocketdoctor.ai \nCall: +1 (778) 819 8321\n\nCautionary Statements\n\nThis news release contains forward-looking statements relating to the future\noperations of Rocket Doctor AI Inc. and other statements that are not\nhistorical facts. Forward-looking statements are often identified by terms\nsuch as \"will,\" \"may,\" \"should,\" \"anticipate,\" \"expects,\" \"intends,\" \"plans,\"\n\"believes,\" \"estimates,\" \"projects,\" \"forecasts,\" \"positioned\" and similar\nexpressions. All statements other than statements of historical fact included\nin this release are forward-looking statements, including, without limitation,\nstatements regarding: the Company's expectation of strong operational\nperformance continuing into 2026; the anticipated increase in U.S. patient\nvisits emanating from the Company's payer agreements in California, New York,\nand Maryland, and the Company's ability to monetize its access to\napproximately 21 million in-network patients; the Company's strategy to scale\nits physician network and patient marketplace across North America; the\nCompany's intention to prioritize the expansion of its payer partnership\nportfolio, both through new clients and the deepening of existing\nrelationships; the Company's multi-state expansion strategy and the broadening\nof its clinical footprint throughout the remainder of 2026; the Company's\npursuit of strategic partnerships to white-label its digital health platform\nand the scalability of that pathway; the Company's integration of AI and\nautomation across its core platforms, and the anticipated optimization of\nclinical workflows, internal efficiencies, and long-term margin expansion; the\nadvancement of the Company's partnership with Rush River Research under the\nUS$2 million NIH grant, and the expected impact of that program through 2026;\nthe successful integration of Alea Health Holdings Ltd. and the anticipated\nenhancement of the Company's clinical capabilities, Global Library of\nMedicine, and position in AI-driven mental health solutions; and  the\nCompany's use of proceeds from its private placement financing to support U.S.\nexpansion, product development, and working capital.\n\nSuch forward-looking statements involve known and unknown risks,\nuncertainties, and other factors that may cause the actual results,\nperformance, or achievements of the Company to be materially different from\nany future results, performances, or achievements expressed or implied by such\nforward-looking statements. There can be no assurance that such statements\nwill prove to be accurate. Important factors that could cause actual results\nto differ materially from the Company's expectations include, but are not\nlimited to: the Company's ability to successfully grow and monetize its U.S.\npayer relationships; competition in the digital healthcare and telehealth\nmarkets; the Company's ability to attract and retain physicians and patients\non its platform; regulatory risks in the healthcare industry in Canada and the\nUnited States; reliance on third-party payers and partners; the Company's\nability to successfully integrate acquired businesses, including Alea Health\nHoldings Ltd.; the Company's ability to continue to secure research funding\nand execute on federal grant programs; general economic conditions; and other\nrisks detailed from time to time in the filings made by Rocket Doctor AI Inc.\nwith securities regulators.\n\nThe reader is cautioned that assumptions used in the preparation of any\nforward-looking information may prove to be incorrect. Events or circumstances\nmay cause actual results to differ materially from those predicted, as a\nresult of numerous known and unknown risks, uncertainties, and other factors,\nmany of which are beyond the control of Rocket Doctor AI Inc. The reader is\ncautioned not to place undue reliance on any forward-looking information. Such\ninformation, although considered reasonable by management at the time of\npreparation, may prove to be incorrect and actual results may differ\nmaterially from those anticipated. Forward-looking statements contained in\nthis news release are expressly qualified by this cautionary statement. The\nforward-looking statements contained in this news release are made as of the\ndate of this news release and Rocket Doctor AI Inc. will only update or revise\npublicly the included forward-looking statements as expressly required by\nCanadian securities law."},"type":"article","timestamp":"2026-05-04T12:00:00.540249767Z","server_sent_at_ms":1777896000540},"received_at":"2026-05-04T12:00:00.606Z","source_url":"https://www.globenewswire.com/news-release/2026/05/04/3286640/0/en/rocket-doctor-ai-reports-strong-2025-results-validating-physician-led-model-with-key-u-s-payer-contracts-and-ai-innovation.html"},"analysis":{"id":"13678","press_release_id":"18864","analysis_json":{"industry":{"label":"Health Care Equipment & Services","sector":"Health Care"},"redFlags":["Cash balance decreased to $641,779 from $1.89 million in Q3, raising liquidity concerns despite recent financing","Net loss widened to $7.3 million in Q4 from $3.5 million in Q3"],"eventType":"earnings","narrative":"Rocket Doctor AI reported FY2025 revenue of $1.739 million, a significant increase driven by the acquisition of Rocket Doctor Inc., and achieved over 30% sequential revenue growth in Q4 to $697,340.\n\nThe company validated its U.S. expansion strategy by securing in-network contracts covering over 21 million lives, including major agreements in California, New York, and Maryland, while U.S. revenue contributed less than 3% to the 2025 total.\n\nTo fund this scaling, the company closed a $5.2 million private placement in January 2026 and was awarded a $500,000 NIH grant, aiming to leverage its access to the new payer network for growth in 2026.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Rocket Doctor AI transitions to commercialization with 30% Q4 growth and 21M-member U.S. payer access."},"keyFigures":{"revenue":"$1.739 million","guidance":"Expecting strong operational performance to continue into 2026; emphasis on increasing US patient visits from 21 million in-network patients","revenueYoy":"increase compared to $10,990 in 2024","customDimensions":{"q3_revenue":"$529,123","q4_revenue":"$697,340","net_loss_q4":"$7.3 million","grant_awarded":"US $500,000","gross_margin_q4":"84%","q4_seq_growth_pct":"31.8%","us_in_network_members":"over 21 million","adjusted_ebitda_loss_q4":"$2.1 million","cash_equivalents_dec_31":"$641,779"}},"quotedText":"2025 was a foundational year for Rocket Doctor AI as we transitioned from proving our concept to demonstrating the potential scalability of our physician-led model.","namedEntities":{"people":[{"name":"Dr. Essam Hamza","role":"CEO"},{"name":"Dr. Suzanne Caccamese","role":"Maryland Medical Lead"}],"products":["Global Library of Medicine (GLM)"],"companies":[{"name":"Rocket Doctor AI Inc.","ticker":"AIDR"},{"name":"Rocket Doctor Inc.","relationship":"subsidiary"},{"name":"Alea Health Holdings Ltd.","relationship":"target"},{"name":"U.S. National Institutes of Health","relationship":"grantor"},{"name":"Health Cities","relationship":"partner"},{"name":"CAN Health Network","relationship":"partner"},{"name":"Lethbridge County","relationship":"partner"},{"name":"Rush River Research","relationship":"partner"}],"dollarAmounts":[{"amount":"$1.739 million","context":"FY2025 Annual Revenue"},{"amount":"$697,340","context":"Q4 2025 Revenue"},{"amount":"$529,123","context":"Q3 2025 Revenue"},{"amount":"$7.3 million","context":"Net comprehensive loss Q4"},{"amount":"$2.1 million","context":"Adjusted EBITDA loss Q4"},{"amount":"$641,779","context":"Cash and cash equivalents Dec 31, 2025"},{"amount":"$5.2 million","context":"Gross proceeds from Jan 2026 private placement"},{"amount":"US $500,000","context":"SBIR grant from NIH"},{"amount":"$2.05 million","context":"Gross proceeds from exercise of warrants"}]},"materialImpact":{"score":4,"reasoning":"Significant Q4 sequential revenue growth (over 30%), record annual revenue driven by acquisition, and major US payer contracts opening a 21M member market. While the company is still loss-making and cash balance is tight, the validation of the US payer model and subsequent $5.2M financing marks a pivotal transition from proof-of-concept to scaling."},"tickerRelevance":{"others":[],"primary":"AIDR"},"globalImportance":20,"audienceRelevance":15,"eventTypeSecondary":["guidance_update","partnership"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"earnings_and_strategic_validation","sectorWeight":"digital_health"}},"event_type":"earnings","event_type_secondary":["guidance_update","partnership"],"sentiment":"bullish","material_impact_score":4,"narrative":"Rocket Doctor AI reported FY2025 revenue of $1.739 million, a significant increase driven by the acquisition of Rocket Doctor Inc., and achieved over 30% sequential revenue growth in Q4 to $697,340.\n\nThe company validated its U.S. expansion strategy by securing in-network contracts covering over 21 million lives, including major agreements in California, New York, and Maryland, while U.S. revenue contributed less than 3% to the 2025 total.\n\nTo fund this scaling, the company closed a $5.2 million private placement in January 2026 and was awarded a $500,000 NIH grant, aiming to leverage its access to the new payer network for growth in 2026.","key_figures":{"revenue":"$1.739 million","guidance":"Expecting strong operational performance to continue into 2026; emphasis on increasing US patient visits from 21 million in-network patients","revenueYoy":"increase compared to $10,990 in 2024","customDimensions":{"q3_revenue":"$529,123","q4_revenue":"$697,340","net_loss_q4":"$7.3 million","grant_awarded":"US $500,000","gross_margin_q4":"84%","q4_seq_growth_pct":"31.8%","us_in_network_members":"over 21 million","adjusted_ebitda_loss_q4":"$2.1 million","cash_equivalents_dec_31":"$641,779"}},"named_entities":{"people":[{"name":"Dr. Essam Hamza","role":"CEO"},{"name":"Dr. Suzanne Caccamese","role":"Maryland Medical Lead"}],"products":["Global Library of Medicine (GLM)"],"companies":[{"name":"Rocket Doctor AI Inc.","ticker":"AIDR"},{"name":"Rocket Doctor Inc.","relationship":"subsidiary"},{"name":"Alea Health Holdings Ltd.","relationship":"target"},{"name":"U.S. National Institutes of Health","relationship":"grantor"},{"name":"Health Cities","relationship":"partner"},{"name":"CAN Health Network","relationship":"partner"},{"name":"Lethbridge County","relationship":"partner"},{"name":"Rush River Research","relationship":"partner"}],"dollarAmounts":[{"amount":"$1.739 million","context":"FY2025 Annual Revenue"},{"amount":"$697,340","context":"Q4 2025 Revenue"},{"amount":"$529,123","context":"Q3 2025 Revenue"},{"amount":"$7.3 million","context":"Net comprehensive loss Q4"},{"amount":"$2.1 million","context":"Adjusted EBITDA loss Q4"},{"amount":"$641,779","context":"Cash and cash equivalents Dec 31, 2025"},{"amount":"$5.2 million","context":"Gross proceeds from Jan 2026 private placement"},{"amount":"US $500,000","context":"SBIR grant from NIH"},{"amount":"$2.05 million","context":"Gross proceeds from exercise of warrants"}]},"model_name":"glm-4.7","prompt_hash":"sha256:a2703c5a1b5285fe","schema_hash":"sha256:1f8af1196c7db48c","created_at":"2026-05-04T13:58:29.088Z","global_importance":20,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"earnings_and_strategic_validation","sectorWeight":"digital_health"}},"durationMs":268584,"modelName":"glm-4.7"}}